会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Inhibitors of C-FMS kinase
    • US20050113566A1
    • 2005-05-26
    • US10970903
    • 2004-10-22
    • Mark PlayerNand BaindurBenjamin BrandtNaresh ChadhaRaymond PatchDavoud AsgariTaxiarchis Georgiadis
    • Mark PlayerNand BaindurBenjamin BrandtNaresh ChadhaRaymond PatchDavoud AsgariTaxiarchis Georgiadis
    • A61K31/16A61K31/195A61K31/452A61K31/4545C07D223/12C07D265/30C07D279/12C07D307/68C07D405/12C07D409/12
    • C07D405/12C07D307/68C07D409/12
    • The invention relates to compounds of Formula I: wherein A is phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of -C1-6 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, sulfonamidoalkyl, guanidinoalkyl, heteroaryl, halogen, hydroxy, —CF3, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, —OCF3, —OCO-alkyl, —CORA, —CN, —C(NH)NH2, —COORa, —CONRaRb, —N(Ra)CORb, —NO2, —SO2Ra, —SO3Ra or —SO2NRaRb; or a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with one or more of -C1-6 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, sulfonamidoalkyl, guanidinoalkyl, heteroaryl, halogen, hydroxy, —CF3, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, —OCF3, —OCO-alkyl, —CORa, —CN, —C(NH)NH2, —COORa, —CONRaRb, —N(Ra)CORb, —NO2, —SO2Ra, —SO3Ra or —SO2NRaRb; R1 is —H, aryl, —CORa, —CORa, —COORa, —CONRaRb, —SO2Ra or —SO2NRaRb; X is —CO—, —C(═NH)—, —CS—, —CON(Ra)—, —CS(NRa)—, —SO2— or —CRaRb—; Y is —S—, —SO—, —SO2—, —O— or direct link; R2 is alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which may be optionally substituted with one or more halogens; and W is phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C1-4 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, halogen, hydroxy, —CF3, alkoxy, aryloxy, arylalkoxy, —OCF3, —CORa, —CN, —C(NH)NH2, —COORa, —CONRaRb, —NHCORaRb, —NHSO2Ra, —NO2, —SORa, —SO3Ra or —SO2NRaRb; or a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heterocyclic or heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with -C1-6 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, halogen, hydroxy, —CF3, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, —OCF3, —OCO-alkyl, —OCO-alkylamino, —OCO-alkylamido, CORa, —CN, —C(NH)NH2, —COORa, —CONRaRb, —N(Ra)CORb, —NO2, —SO2Ra, —SO3Ra or —SO2NRaRb; as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.
    • 8. 发明授权
    • Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators
    • 取代的噻唑烷二酮吲唑,吲哚和苯并三唑作为雌激素相关受体α调节剂
    • US08796256B2
    • 2014-08-05
    • US13114084
    • 2011-05-24
    • Gilles BignanWing CheungMicheal GaulHui HuangXun LiRaymond PatchSharmila PatelMark PlayerGuozhang XuBao-Ping ZhaoJian Liu
    • Gilles BignanWing CheungMicheal GaulHui HuangXun LiRaymond PatchSharmila PatelMark PlayerGuozhang XuBao-Ping ZhaoJian Liu
    • C07D417/06
    • C07D417/06
    • The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
    • 本发明涉及式(I)化合物,制备这些化合物的方法,组合物,中间体及其衍生物,用于治疗包括但不限于强直性脊柱炎,动脉粥样硬化,关节炎(如类风湿性关节炎,感染性关节炎,儿童期 关节炎,牛皮癣关节炎,反应性关节炎),骨相关疾病(包括与骨形成相关的疾病),乳腺癌(包括对抗雌激素治疗无反应的那些),心血管疾病,软骨相关疾病(如软骨损伤/损失, 软骨变性和与软骨形成相关的软骨变性,软骨发育不全,软骨肉瘤,慢性背部损伤,慢性支气管炎,慢性炎症性气道疾病,慢性阻塞性肺病,糖尿病,能量稳态障碍,痛风,假性血糖,脂质障碍,代谢综合征,多发性 骨髓瘤,肥胖症,骨关节炎,成骨不全,骨质溶解骨 骨质疏松症,骨质疏松症,佩吉特氏病,牙周病,风湿性多肌痛,莱特综合征,重复性应激损伤,高血糖,升高的血糖水平和胰岛素抵抗。
    • 10. 发明申请
    • MULTI-DIMENSIONAL OBJECTS
    • 多维对象
    • US20120102453A1
    • 2012-04-26
    • US12908888
    • 2010-10-21
    • Raymond PatchRajeev Chauhan
    • Raymond PatchRajeev Chauhan
    • G06F9/44G06F17/30
    • G06F8/24G06F9/4488
    • Architecture that enables a software object to be a multi-dimensional object by associating additional dimensions to the object. The object, in addition to the actual data dimension, is now provided with inherent object dimensions that include, but are not limited to, a localization dimension, security dimension, version dimension, personalization dimension, and attributes dimension, for example. The actual data dimension and one or more inherent object dimensions can be added, changed, or modified in realtime. A mapping component maps object relationships between an in-memory form and a tabular form storable in a database. An application programming interface facilitates interaction with the object, and the actual data dimension, and the one or more inherent object dimensions.
    • 通过将附加维度与对象相关联来使软件对象成为多维对象的体系结构。 除了实际数据维度之外,该对象现在具有固有的对象维度,例如包括但不限于定位维度,安全维度,版本维度,个性化维度和属性维度。 实际数据维度和一个或多个固有对象维度可以实时添加,更改或修改。 映射组件映射内存中的形式与数据库中可存储的表格之间的对象关系。 应用程序编程界面便于与对象,实际数据维度以及一个或多个固有对象维度进行交互。